Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$11,298 Mln
Revenue (TTM)
$2,299 Mln
Net Profit (TTM)
$0 Mln
ROE
0.3 %
ROCE
-- %
P/E Ratio
19.1
P/B Ratio
5.5
Industry P/E
--
EV/EBITDA
12.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$2.2
Face value
--
Shares outstanding
272,708,000
CFO
$3,591.92 Mln
EBITDA
$2,393.43 Mln
Net Profit
$2,144.59 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Exelixis (EXEL)
| 25.5 | 15.5 | 13.1 | 89.7 | 32.1 | 14.1 | 28.1 |
|
BSE Sensex*
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Exelixis (EXEL)
| 38.4 | 49.6 | -12.3 | -8.9 | 13.9 | -10.4 | -35.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Exelixis (EXEL)
|
41.8 | 11,298.3 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19.1 | 5.5 |
| 51.5 | 8,079.8 | 1,208.8 | 131.7 | 13.4 | 6.3 | 62.1 | 3.9 | |
| 128.2 | 8,274.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 151.9 | 7,421.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 54.0 | 10,499.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.3 | |
| 54.5 | 6,635.5 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14.3 | 13.9 | |
| 297.2 | 6,535.3 | 317.4 | -391.6 | -118.9 | -52.6 | -- | 9.2 | |
| 304.0 | 8,688.9 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.4 | 14.6 | |
| 27.4 | 10,732.1 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.1 | |
| 125.0 | 12,288.6 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.4 | 4.9 |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced... renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. Address: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 Read more
Co-Founder & Chair of the Board
Dr. Stelios Papadopoulos Ph.D.
Co-Founder & Chair of the Board
Dr. Stelios Papadopoulos Ph.D.
Headquarters
Alameda, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Exelixis Inc (EXEL) stood at $ 3,236 Mln as on 31-Mar-25
The share price of Exelixis Inc (EXEL) is $41.78 (NASDAQ) as of 12-Jun-2025 16:00 EDT. Exelixis Inc (EXEL) has given a return of 32.06% in the last 3 years.
Exelixis Inc (EXEL) has a market capitalisation of $ 11,298 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Exelixis Inc (EXEL) is 5.49 times as on 12-Jun-2025, a 112% premium to its peers’ median range of 2.59 times.
The P/E ratio of Exelixis Inc (EXEL) is 19.09 times as on 12-Jun-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Exelixis Inc (EXEL) and enter the required number of quantities and click on buy to purchase the shares of Exelixis Inc (EXEL).
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. Address: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502
The CEO & director of Dr. Stelios Papadopoulos Ph.D.. is Exelixis Inc (EXEL), and CFO & Sr. VP is Dr. Stelios Papadopoulos Ph.D..
There is no promoter pledging in Exelixis Inc (EXEL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,237
|
|
|
1,076
|
|
|
1,041
|
|
|
899
|
|
|
827
|
|
|
781
|
|
|
703
|
|
|
664
|
|
|
631
|
| Exelixis Inc. (EXEL) | Ratios |
|---|---|
|
Return on equity(%)
|
29.21
|
|
Operating margin(%)
|
35.43
|
|
Net Margin(%)
|
27.99
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Exelixis Inc (EXEL) was $0 Mln.
$0.35
(
